Publications by authors named "Laszlo Revesz"

18Publications

Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.

ACS Med Chem Lett 2019 Oct 6;10(10):1467-1472. Epub 2019 Sep 6.

Global Discovery Chemistry, Autoimmunity, Transplantation & Inflammation, Chemical Biology & Therapeutics, and PK Sciences, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.9b00317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792172PMC
October 2019

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.

Bioorg Med Chem Lett 2010 Aug 11;20(15):4719-23. Epub 2010 Apr 11.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.04.023DOI Listing
August 2010

Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy.

Bioorg Med Chem Lett 2010 Feb 3;20(3):1293-7. Epub 2009 Nov 3.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.10.138DOI Listing
February 2010

Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.

Bioorg Med Chem Lett 2008 Dec 11;18(23):6142-6. Epub 2008 Oct 11.

Novartis Institutes for BioMedical Research, global Discovery Chemistry, WSJ-88.508, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2008.10.039DOI Listing
December 2008

Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.

Bioorg Med Chem Lett 2006 Jan 24;16(2):262-6. Epub 2005 Oct 24.

Novartis Institutes for BioMedical Research, Global Discovery Chemistry, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.10.015DOI Listing
January 2006

Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.

Bioorg Med Chem Lett 2006 Jan 19;16(1):108-12. Epub 2005 Oct 19.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.09.035DOI Listing
January 2006

Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.

Bioorg Med Chem Lett 2005 Dec 28;15(23):5160-4. Epub 2005 Sep 28.

Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Autoimmunity and Transplantation, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.08.057DOI Listing
December 2005

SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.

Bioorg Med Chem Lett 2004 Jul;14(13):3601-5

Novartis Institutes for BioMedical Research, Arthritis and Bone Metabolism, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2004.03.111DOI Listing
July 2004

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.

Bioorg Med Chem Lett 2004 Jul;14(13):3595-9

Novartis Institutes for BioMedical Research, Arthritis & Bone Metabolism, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2004.03.106DOI Listing
July 2004

Effects of a mitogen-activated protein kinase inhibitor on allergic airways inflammation in the rat studied by magnetic resonance imaging.

Eur J Pharmacol 2003 Dec;482(1-3):319-24

Discovery Technologies Center, Novartis Institutes for BioMedical Research, Lichstr. 35, WSJ-386.2.09, CH-4002, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2003.09.052DOI Listing
December 2003

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.

Bioorg Med Chem Lett 2002 Aug;12(16):2109-12

Arthritis and Bone Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(02)00336-0DOI Listing
August 2002